Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information
Phone(415) 362-4022



San Francisco, USA
One Embarcadero Center
37th Floor
San Francisco, CA, 94111


Co-founder and Managing Director
Founding Partner and Managing Director
Managing Director
Managing Director

Service Providers


Alta Partners

Alta Partners is a leading venture capital firm in life sciences, funding over 130 companies in the industry since 1996. Their diverse and integrated team brings together a powerful depth of knowledge and experience, delivering tangible results for their companies and their investors.

Recent Milestones


Company Date Round Size Participants
Lumena Pharmaceuticals 3/2014Series B$45M6
ZS Pharma 3/2014Series D$55M9
Lithera 2/2014Series C$8M3
Sutro Biopharma 12/2013Series D$26M6
Zafgen 12/2013Series E$45M4
Immune Design 10/2013Series C$49M6
aTyr Pharma 7/2013Series D$49M4
Kite Pharma 5/2013Series A$20M1
Lumena Pharmaceuticals 5/2013Series A$23M3
Esperion Therapeutics 4/2013Venture Round$33M7
Achaogen 3/2013Private Equity$18.9M7
Carbylan BioSurgery 1/2013Series C$6M3
Allakos 12/2012Partial Close$10M4
Lithera 12/2012Series C$20.6M5
Zafgen 12/2012Series D$21M3
Kiadis Pharma 11/2012Venture Round€10M4
Applied Genetics Technologies Corporation 11/2012Series B$37.5M6
ZS Pharma 10/2012Series C$46M6
Sutro Biopharma 5/2012Series C$16.5M5
SARcode Bioscience 7/2011Series B$44M4
Aerie Pharmaceuticals 3/2011Series B$41.4M5
Chimerix 2/2011Series F$45M8
PneumRx 1/2011Venture Round$33M8
Sutro Biopharma 11/2010Series C$36.5M5
aTyr Pharma 10/2010Series C$23M4
Pathwork Diagnostics 10/2010Series C$30M6
Immune Design 7/2010Series B$32M5
Cerenis Therapeutics 7/2010Series C€40M7
Cara Therapeutics 7/2010Series D$15M8
Trevena 7/2010Series B$35M4
Calistoga Pharmaceuticals 6/2010Series C$40M6
Nereus Pharmaceuticals 6/2010Series E$20M7
Virobay 6/2010Venture Round$10M2
Foldrx Pharmaceuticals 6/2010Venture Round$29M7
Achaogen 4/2010Series C$56M7
TransMedics 3/2010Series E$36M11
Virobay 1/2010Debt$300k3
Coapt Systems 12/2009Debt$3.72M8
CymaBay Therapeutics 11/2009Venture Round$8.6M12
aTyr Pharma 9/2009Series C$12M3
Chimerix 8/2009Series E$16.1M4
Avid Radiopharmaceuticals 5/2009Series D$34.5M8
Calistoga Pharmaceuticals 5/2009Series B$30M4
Aerovance 4/2009Venture Round$38M8
Sunesis Pharmaceuticals 4/2009Venture Round$43.5M9
Sutro Biopharma 3/2009Series B$15M2
Intradigm Corporation 1/2009Series B$21.4M8
Xelerated 8/2008Series E$13M5
Sierra Surgical 7/2008Series B$14.5M2
Immune Design 7/2008Series A$18M3
Vaccsys 6/2008Venture Round$9M3
Esperion Therapeutics 5/2008Series A$22.8M4
Trevena 3/2008Series A$24M4
Sonexa Therapeutics 1/2008Series A$30M5
Taligen Therapeutics 1/2008Series B$65M4
Sutro Biopharma 12/2007Series B$21M2
Excaliard Pharmaceuticals 11/2007Series A$15.5M3
Carbylan BioSurgery 11/2007Series B$20M3
agámi Systems 11/2007Series C$50M8
Sierra Surgical 8/2007Series A$7.1M2
Agensys 7/2007Series D$41.3M8
Paracor Medical 6/2007Series D$44M8
Ceregene 6/2007Series C$28M6
nCircle Network Security 5/2007Venture Round$5M4
Xelerated 5/2007Series D$23M5
CymaBay Therapeutics 4/2007Series D$32M16
aTyr Pharma 4/2007Series B$10.5M3
TransMedics 4/2007Series D$25.5M9
Coapt Systems 3/2007Series E$22.6M7
Aerovance 3/2007Series C$60M6
ChemoCentryx 3/2007Series D$29.8M5
Intarcia Therapeutics 3/2007Series B$50M5
Phenomix 3/2007Series C$55M10
Calistoga Pharmaceuticals 3/2007Series A$21M4
Sanarus Medical 2/2007Series E$15M6
SARcode Bioscience 12/2006Venture Round$29M2
Cara Therapeutics 11/2006Series C$19M3
Intradigm Corporation 11/2006Series A$16M5
ChemoCentryx 8/2006Series C$17.7M6
MacroGenics 5/2006Series C$45M11
Aegis Lightwave 3/2006Series D$8M4
iSOCO 2/2006Venture Round$357k3
Netli 2/2006Venture Round$18M7
RedShift Systems 1/2006Series A$12M6
OPAL Therapeutics 10/2005Series A$6M4
Xelerated 4/2005Series C$17M4
ChemoCentryx 6/2004Venture Round$33M5
TransMedics 1/2004Series B$27.6M8



  1. Lumena Pharmaceuticals Secures $45M in Series B Financing ( [edit]
  2. ZS Pharma Completes $55 Million Financing to Advance Its Novel Investigational Treatment for Hyperkalemia ( [edit]
  3. Lithera Raises $8M in Series C Funding ( [edit]
  4. Sutro Biopharma Secures $26M in Series D Financing ( [edit]
  5. Zafgen Secures $45M in Series E Equity Financing ( [edit]
  6. Immune Design Closes an up to $49M Series C Financing ( [edit]
  7. aTyr Pharma Completes $49M Equity Financing ( [edit]
  8. UPDATED: Billionaires back Kite Pharma in $20M raise for cancer immunotherapies ( [edit]
  9. Lumena Pharmaceuticals Announces $23 Million Series A Financing ( [edit]
  10. Esperion Therapeutics Completes $33 Million Preferred Financing to Advance Its Novel Oral LDL-C Lowering Therapy to Later Stage Clinical Trials ( [edit]
  11. VC Funding - Q2 2013 [edit]
  12. Medical Device Daily: Med-Tech Notes - Carbylan BioSurgery, Inc. ( [edit]
  13. SEC ( [edit]
  14. Lithera, Inc. Completes $20.6 Million Equity Financing ( [edit]
  15. Obesity drug developer Zafgen raises $21M ( [edit]
  16. Kiadis Pharma Raises EUR 10 Million in Financing Round ( [edit]
  17. Applied Genetic Technologies Corporation Lands $37.5 Million in Venture Capital Funding ( [edit]
  18. ZS Pharma lands $46 million for kidney and liver drug development ( [edit]
  19. Sutro Closes $16.5 Million Second Tranche of Series C Financing ( [edit]
  20. SARcode Bioscience Closes $44M Series B Financing ( [edit]
  21. SEC ( [edit]
  22. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157 ( [edit]
  23. PneumRx Raises $33M ( [edit]
  24. Sutro Biopharma Secures $36.5M in Series C Financing ( [edit]
  25. aTyr Pharma Secures $23M Financing From Top Tier Venture Investor ( [edit]
  26. Alta Partners Leads $30M Series C For Pathwork Diagnostics ( [edit]
  27. Immune Design Nabs $32M for Targeted Vaccines ( [edit]
  28. Cerenis Therapeutics raises EUR 40 million in series C financing ( [edit]
  29. Cara rounds up $15M for post-op pain drug Read more: Cara rounds up $15M for post-op pain drug ( [edit]
  30. Trevena, Inc.: Series B $35M ( [edit]
  31. Calistoga Pharmaceuticals Raises $40 Million in Series C Financing ( [edit]
  32. Nereus Pharmaceuticals, Inc.: Series E $20M ( [edit]
  33. Drug developer Virobay secures $10M for hepatitis C treatments ( [edit]
  34. FoldRx banks $29M for neurodegenerative drug application ( [edit]
  35. Achaogen Completes $56 Million Series C Financing ( [edit]
  36. TransMedics, Inc.: Series E $36M ( [edit]
  37. Virobay raises $300K to treat hepatitis C and autoimmune disorders ( [edit]
  38. Coapt Systems takes $3.7M for facial rejuvenation ( [edit]
  39. Metabolex ( [edit]
  40. aTyr Pharma, Inc.: Series C $12M ( [edit]
  41. VC insiders inject $16M into Chimerix ( [edit]
  42. Avid Radiopharmaceuticals Closes $34.5 Million Series D Financing ( [edit]
  43. Capital Report Index [edit]
  44. Aerovance inhales $38M for asthma drugs ( [edit]
  45. VCs PIPE $43.5 Million to Sunesis Pharma ( [edit]
  46. Sutro Biopharma lands $15M with protein production ( [edit]
  47. Intradigm Corporation Closes Final Tranche of $21.4 Million Series B Financing; Philip Haworth, Ph.D. Appointed Chief Executive ( [edit]
  48. Xelerated Closes $13 Million Funding Round ( [edit]
  49. Sierra Surgical raises $14.5M for female sterilization ( [edit]
  50. Immune Design Aiming To Make Vaccines That Work Better in a Single Shot ( [edit]
  51. Vaccsys raises $9 million for vaccine research ( [edit]
  52. Esperion Therapeutics Completes $22.75M Series A Financing ( [edit]
  53. Trevena, Inc. Announces $24 Million Series A Financing ( [edit]
  54. Sonexa Therapeutics, Inc. Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments ( [edit]
  55. Taligen Therapeutics Secures Series B Financing ( [edit]
  56. Fundamental Applied Biology, Inc. Completes $21 Million Series B Financing Daniel S. Gold, PhD, Joins as Chief Executive Officer ( [edit]
  57. Excaliard closes $15.5 million Series A financing from Alta Partners, ProQuest Investments and RiverVest Venture Partners ( [edit]
  58. Carbylan Announces $20 Million Series B Financing ( [edit]
  59. Agami Systems Raising $50 Million Funding ( [edit]
  60. Sierra Surgical raises $7.1M for female-sterilization tech ( [edit]
  61. Agensys Raises $41 Million ( [edit]
  62. Paracor raises $44M for heart-failure device that restrains the heart ( [edit]
  63. Ceregene Partners With Genzyme, Inks $28M Series C ( [edit]
  64. EDGAR [edit]
  65. Carrier Ethernet's Xelerated Ventures Forth With $23M ( [edit]
  66. Metabolex ( [edit]
  67. aTyr Pharma Completes $10.5M Series B Round ( [edit]
  68. TransMedics ( [edit]
  69. Coapt Systems, maker of aesthetic surgery implants, raises $22.6M more ( [edit]
  70. Aerovance, asthma treatment company, finishes raising $60M ( [edit]
  71. ChemoCentryx, autoimmune disease drug co., raises $29.84M ( [edit]
  72. Intarcia restarts with $50M for hepatitis, diabetes treatments ( [edit]
  74. Calistoga Pharmaceuticals, a newly formed drug development company, announces its formation and completion of a $21 million Series A financing ( [edit]
  75. Sanuras, breat tumor device company raises $15M ( [edit]
  76. SARcode secured $25 million in financing ( [edit]
  77. Cara Therapeutics Secures $19 Million in Series C Financing. ( [edit]
  79. ChemoCentryx Completes Series C Financing ( [edit]
  80. MacroGenics Raises $45M in Series C Financing - Company to Advance Monoclonal Antibody Clinical Programs ( [edit]
  81. Aegis Semiconductor Secures $8 Million in Series D Financing ( [edit]
  82. EDGAR [edit]
  83. Netli raises $18M funding ( [edit]
  84. RedShift Secures $12 Million in First-Round Financing ( [edit]
  85. Opal Therapeutics raises $6m in series A funding ( [edit]
  86. Xelerated Lands $17 Million in New Funding ( [edit]
  87. ChemoCentryx Raises $33 Million in Private Financing ( [edit]
  88. TransMedics ( [edit]
Edit This Page
Last Edited 3/27/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy